ArticleMethods in molecular biology (Clifton, N.J.)2026
Labeling of Specific Residues of the Multidrug Transporter AcrB with Its Fluorescent Substrate.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gram-negative bacteria possess resistance nodulation cell division (RND)-type drug efflux transporters in the inner membrane that confer a high degree of intrinsic resistance to various drugs. Escherichia coli expresses the most powerful RND-type drug efflux transporter, AcrB, which extrudes various chemical compounds, including antibiotics, by forming a complex with the periplasmic membrane fusion protein AcrA and the outer membrane channel TolC. To date, various reported structures of RND-type drug efflux transporters and AcrA-AcrB-TolC ternary complex have indicated substrate-binding sites and substrate translocation pathways, but their biochemical verification is insufficient.In this chapter, I describe the labeling, purification, and detection of AcrB Cys mutants using tetramethylrhodamine-5-iodoacetamide, a thiol-reactive fluorescent reagent recognized by AcrB, as a substrate. The labeling of substrate-binding sites and substrate translocation pathways of the AcrA-AcrB-TolC system using this method will be useful for elucidating the multidrug transport mechanism of this ternary complex system.
Indexed as
Identifiers
42681246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.